U.S. market Closed. Opens in 1 day 9 hours 13 minutes

SPRO | Spero Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
Revenue96.73M48.58M18.26M9.33M4.74M3.97M1.98M335.00KN/A
Cost of Revenue367.00K1.55M1.12M67.00M65.78M33.88M32.87M26.33M11.00K
Gross Profit96.37M47.03M17.14M-57.67M-61.03M-29.92M-30.89M-26.00M-11.00K
Operating Expenses75.25M79.15M106.23M88.44M67.96M42.81M41.73M33.56M13.33M
Selling, General & Admin25.55M36.48M41.70M21.44M15.59M12.89M10.84M7.22M2.20M
Research & Development51.44M47.59M64.53M67.00M65.78M33.88M32.87M26.33M11.12M
Other Operating Expenses-1.74M-4.93M-395.00K833.00K-13.40M1.14M-4.37MN/A174.00K
Operating Income21.48M-42.20M-87.97M-79.11M-63.22M-42.81M-41.73M-33.22M-13.33M
Other Expenses / Income3.92M-4.22M-1.78M833.00K2.29M1.14M1.84M580.00K174.00K
Before Tax Income25.40M-46.41M-89.76M-78.28M-60.92M-41.66M-46.10M-32.64M-13.15M
Income Tax Expenses2.60M1.61M1.54M-761.00K-750.00K1.14M-363.00K-7.73M-3.17M
Net Income22.81M-48.03M-91.30M-77.52M-60.17M-41.66M-46.10M-25.49M-10.15M
Interest ExpensesN/A2.60M1.94MN/AN/A303.00K303.00KN/AN/A
Basic Shares Outstanding52.70M37.59M30.90M22.39M18.16M16.00M2.59M6.60M6.60M
Diluted Shares Outstanding52.99M37.59M30.90M22.39M18.16M16.00M2.59M6.60M6.60M
EBITDA25.77M-42.26M-87.17M-76.93M-62.47M-42.40M-41.37M-32.94M-13.32M
EBITDA Margin26.64%-87.00%-477.49%-824.59%-1,317.29%-1,069.01%-2,090.30%-9,833.43%0.00%
EBIT25.40M-43.81M-87.82M-78.28M-60.92M-40.22M-46.16M-33.22M-13.33M
EBIT Margin26.26%-90.18%-481.03%-839.01%-1,284.80%-1,013.99%-2,332.34%-9,916.72%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙